Advertisement
Mr. Ward is currently Senior Vice President and President of theCardioVascular sector at Medtronic, Inc. In this role, he is responsible forall worldwide operations of the Coronary, Peripheral, Endovascular, StructuralHeart Disease and Revascularization and Surgical Therapies businesses. UnderMr. Ward's leadership, Medtronic's CardioVascular business has developed andcommercialized numerous products, generating strong growth and approximately$2.1 billion in revenue in fiscal year 2008. Prior to his current role, Mr.Ward served in multiple capacities including: Senior Vice President andPresident of Medtronic Neurological and Diabetes, with responsibility forglobal Movement Disorders, Pain Management, Neurologic Technologies, Diabetes,Gastroenterology and Urology businesses; Vice President and General Manager ofthe Medtronic Drug Delivery Business; and President of Medtronic Neurological.Mr. Ward first joined Medtronic in 1981.
Advertisement
"Scott has helped to bring several new products to market demonstratingextensive skills in regulatory and commercialization strategies, including themanufacture and sale of drug therapies for pain, spasticity, diabetes, cancerand coronary stents," said Timothy S. Nelson, President and Chief ExecutiveOfficer of MAP Pharmaceuticals. "The addition of Scott's product developmentand commercialization experience to the Board of Directors will benefit MAPPharmaceuticals as we continue to advance our two lead drug candidates forpediatric asthma and acute migraine through Phase 3 clinical trials andpotential commercialization."
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals develops and plans to commercialize new therapies forchildren and adults who suffer from chronic conditions that it believes arenot adequately treated by currently available medicines. The company appliesits proprietary inhalation technologies to enhance the therapeutic benefitsand commercial attractiveness of proven drugs while minimizing risk bycapitalizing on their known safety, efficacy and commercialization history.MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. UnitDose Budesonide is being developed for the potential treatment of pediatricasthma, and MAP0004 is being developed for the potential treatment ofmigraine. MAP Pharmaceuticals' pipeline also includes a drug candidate inearly clinical development for the treatment of asthma and chronic obstructivepulmonary disease.
Additional information about MAP Pharmaceuticals can be found athttp://www.mappharma.com.
Forward-Looking Statements
In addition to statements of historical facts or statements of currentconditions, this press release contains forward-looking statements, includingwith respect to MAP Pharmaceuticals' product candidates in clinicaldevelopment. Actual results may differ materially from current expectationsbased on risks and uncertainties affecting MAP Pharmaceuticals' business,including, without limitation, risks and uncertainties relating to thedevelopment, clinical testing and potential commercialization these productcandidates. The reader is cautioned not to unduly rely on the forward-lookingstatements contained in this press release. MAP Pharmaceuticals expresslydisclaims any intent or obligation to update these forward-looking statements,except as required by law. Additional information on potential factors thatcould affect MAP Pharmaceuticals' results and
